Ignite Creation Date:
2025-12-24 @ 11:18 PM
Ignite Modification Date:
2026-01-01 @ 10:27 PM
Study NCT ID:
NCT06008756
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-11-13
First Post:
2023-08-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-10-09
Start Date Type:
ACTUAL
Primary Completion Date:
2029-11-29
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-11-29
Completion Date Type:
ESTIMATED
First Submit Date:
2023-08-17
First Submit QC Date:
None
Study First Post Date:
2023-08-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-11
Last Update Post Date:
2025-11-13
Last Update Post Date Type:
ESTIMATED